The Tohoku journal of experimental medicine
-
Tohoku J. Exp. Med. · Oct 2024
Randomized Controlled TrialExpression of CD4+T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis.
Myeloproliferative disorders (MPDs) are rare diseases in which the bone marrow produces too many red, white, or platelets. Myeloproliferative disorders are neither acute nor leukaemia. To study ruxolitinib's effect on MPD therapy and CD4+ T cell expression. ⋯ The study group had increased CD4 and CD4/CD8 levels, whereas the control group had lower CD8 and Treg levels. The study group had a greater 1-year survival rate than the control group, but the control group had lower mortality and adverse event rates. In JAK2V617F-positive MPD patients, ruxolitinib reduces JAK2V617F gene expression, myelofibrosis, and therapeutic impact.
-
Tohoku J. Exp. Med. · Oct 2024
Difficulty Falling Asleep, Nocturnal Awakening, Sleep Dissatisfaction, and Irritability in the General Population.
Sleep disturbance is characterized by problems with sleep quantity and quality. However, the exact mechanisms and factors underlying sleep dissatisfaction in the general population remains unclear. This cross-sectional study collected sleep data and irritability level from individuals who visited hospitals for medical checkups or with unexplained physical symptoms using self-report questionnaires. ⋯ In summary, major factors underlying sleep dissatisfaction in the general population included difficulty falling asleep and nocturnal awakening. Irritability was associated with difficulty falling asleep and sleep dissatisfaction. Carefully evaluating each of these sleep-related subscales and irritability may be beneficial in managing individuals with sleep problems.
-
Tohoku J. Exp. Med. · Oct 2024
Analysis of Abnormal Expression of MiR-320b in Serum of Patients with Hypertension and its Clinical Value.
Studies have found that miRNAs can participate in the progression of hypertension by affecting the function of endothelial cells and inflammatory response. This study was to investigate the clinical value of miR-320b in patients with hypertension and its potential effect on Angiotensin (Ang) II-induced endothelial cells. Real-time quantitative PCR (RT-qPCR) was used to detect the differential expression of miR-320b in all subjects, and the diagnostic value of miR-320b in hypertension was further evaluated by the receiver operating characteristic (ROC) curve. ⋯ Cell analysis proved that Ang II induced the decrease of HUVECs viability and the activation of apoptosis and inflammation, while overexpression of miR-320b inhibited Ang II-induced apoptosis and inflammation and promoted cell growth (P < 0.05). Luciferase reporter gene showed that AKT3 was the downstream target gene of miR-320b. In summary, this study suggests that miR-320b alleviates Ang II-induced apoptosis, inflammation and the inhibition of cell viability by targeting AKT3 expression, and may be involved in the pathogenesis of hypertension.